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Abstract

Medical Center

Background

Sickle cell crisis hospitalizations are emotionally and financially burdensome to patients and
healthcare systems, and processes to decrease the frequency or length of stay of these
crises should be examined.
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Methods

This is a multicenter retrospective hospital record review of sickle cell crisis hospitalizations
as defined by ICD-10 codes (D57.1-4), from January 2016 through December 2019, examining inpatient medication administration records and length of stay among admitted adults
aged 18–65 years. Patient controlled analgesia orders using morphine, hydromorphone, fentanyl and/or merperidine at any point of an admission (n=188) were compared to admissions
without any patient-controlled analgesia orders (n=2,159). The primary end point was hospital length of stay in days. A secondary analysis examining patients with or without greater
than four admissions was also conducted.

Results

The 1,675 patients who met criteria comprised 2,347 sickle cell hospitalizations during the
four years examined. Of those admissions, 188 had at least one patient-controlled analgesic
documented in their chart and had an average length of stay of 4.54 days (SD 3.34). The
2,159 admissions without any patient-controlled analgesia had an average length of stay of
5.74 days (SD 4.64). The difference of 1.2 days between the groups was statistically significant (p≤0.0001) using a Wilcoxon signed-rank test.

Conclusion

Among patients with sickle cell crises who required inpatient hospitalizations, the use of
patient-controlled analgesia demonstrated a statistically significant reduction of 1.2 days in
their total length of stay. These findings support potentially changing hospital protocols to
increase patient-controlled analgesia utilization.

Keywords

sickle cell disease; sickle cell anemia; family medicine; sickle cell crisis; hematology; patientcontrolled analgesia; hospitalization; length of stay

Introduction

Sickle cell anemia results from homozygosity
for a point mutation in the b-subunit of the
hemoglobin (Hb) molecule (b6 GAG->GTG,
Glutamic acid->Valine).1 This variant hemoglobin (Hb S) polymerizes upon deoxygenation,
leading to the distortion of the red blood cell
(RBC) to an elongated, “sickle-like” shape. The

RBCs that contain deoxy Hb S polymer are rigid, less deformable and can cause microvascular
occlusion, and also have a much-shortened
lifespan compared to normal RBCs. They also
interact and activate with vascular endothelium
and white blood cells, leading to the generation
of a chronic inflammatory state.2 The combination of increased RBC destruction (hemo-
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lysis), microvascular occlusion and a chronic
inflammatory state culminates in chronic organ
damage involving multiple systems. Combined
heterozygosity for the sickle mutation and
certain other Hb variants such as Hb C, D, E
and O-Arab and b-thalassemia can also result in
different forms of sickle cell disease (SCD). The
hallmark of sickle cell disease is the vaso-occlusive crisis (VOC), or painful episodes, which
occur with varying frequencies in different patients. These episodes are associated with severe, excruciating pain, most commonly in the
lower back, legs, arms and occasionally in the
chest and abdomen. They last from a few hours
to several weeks and require emergency department (ED) visits and hospitalizations. The
treatment of these episodes requires parenteral opioid administration and intravenous (IV)
fluids in many instances. VOCs are associated
with microvascular occlusion, ischemia-reperfusion injury, increased inflammation and in
certain instances can lead to more serious and
life-threatening complications such as acute
chest syndrome and multi-organ failure. VOCs
are the most frequent cause of health care encounters in SCD patients, and account for 95%
of hospitalizations in this patient population.
There are various treatment modalities currently in practice for primary prevention of
VOC in sickle cell patients, including hydroxyurea L-glutamine, and more recently FDA-approved monoclonal anti-P selectin antibody,
crizanlizumab (Adakveo).3 Routine management with a health care provider, diet, attention to individualized triggers, optimal sleep
and psychosocial support are all considered
methods of primary prevention as well.
Despite primary prevention methods, acute
VOCs can still occur and management is directed towards pain control and prevention of
secondary complications. Pain is the most common complication of VOC in SCD and the most
common reason patients seek medical care.4
The National Heart, Lung and Blood Institute
(NHLBI) strongly recommends as standard
of care, prompt administration of parenteral
opioids for severe pain within 30 minutes of
ED triage.5 A moderate recommendation of
around the clock opioid administration by patient-controlled analgesia (PCA) has also been
implemented among standards of care.6 PCA
appears to be preferred by patients and has a
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better 72-hour discharge rate when compared
to patient requested infusions of analgesia.6,7
The primary purpose of this study was to reassess if PCA utilization for the management of
pain reduces the overall length of stay (LOS)
for patients admitted with VOC.

Methods

Study Design and Participants

A multicenter, retrospective, case series review
was performed across 23 hospitals within HCA
Healthcare’s South Atlantic and East Florida
divisions in the states of South Carolina, Georgia and Florida. The sampling frame included
all cases of sickle cell crisis that occurred from
January 2016 through December 2019. Participants were adults aged 18–65 years who had
associated ICD-10 codes attributed to sickle
cell crisis (ICD-10; D57.1, D57.2, D57.3, D57.4)
and were admitted from the ED to inpatient
status for further management. Exclusion criteria included patients admitted for a principal
diagnosis not related to sickle cell crisis, and
patients who did not fall within the designated
age range. Physician orders, inpatient medication administration record and discharge time
were reviewed to determine if PCA was used
during the course of a patient’s hospital stay,
as well as their total LOS in days. Medications
considered for PCA use were IV morphine,
hydromorphone, fentanyl, oral hydrocodone
and oral oxycodone. PCA may be administered
either basal/continuous with demand doses
or demand doses only. The electronic health
record could not differentiate between the two
types and the results were grouped into use of
PCA or not. During an admission, PCA usage
of either kind was confirmed if the medication
of interest was administered following documentation of a physician order for PCA or PCA
pump.

Study Oversight and Data Collection

Permission to obtain demographic and clinical
data was granted through the HCA Healthcare
enterprise data warehouse (EDW) approval
process in June 2019 and an institutional review
board exempt determination was obtained.
Data were obtained through two different
electronic medical record systems: Meditech
and Epic. Meditech amassed data from 22
hospitals, while Epic was exclusively used at
Memorial University Medical Center in Savan-
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nah, GA. The de-identified data were sent to an
enterprise-level data analyst who merged and
then stored the data securely in a virtual desktop interface (VDI) before granting access to a
project-specific data specialist who completed
statistical analysis and confirmed data validity.
In February 2020, a second data request using
the same process described above was completed to include all of 2019 in the data set.

Statistical Analysis

To gain a better understanding of the patterns
and trends present within the data, a series of
preliminary descriptive statistics were conducted. Categorical variables were summarized
using frequency counts, percentages and a
series of bivariate statistics (i.e., cross tabulations) while measures of central tendency were
generated for the continuous variables.
When examining the potential influence of
at least one PCA administration on patients’
overall length of stay, the following approach
was employed: All subjects were formatted
and analyzed based on the binary PCA variable
(0 = no PCA during a patient’s admission; 1 =
at least one PCA during admission). Because
we could not confirm the assumption that our
primary variable of interest (overall admission
LOS) was normally distributed via a Kolmogorov-Smirnov analysis, a non-parametric
approach via a Wilcoxon two sample test was
used to evaluate our primary research question. All inferential statistics were 2-tailed
and with a tolerance for nominal type 1 error
(alpha) of 0.05.

We anticipated that frequent admissions by an
individual could impact their LOS; therefore,
all subjects were categorized based on his/her
number of unique encounters over the fouryear period (2016–2019) of interest. An arbitrary delineation was assigned at greater than
or equal to four unique patient admissions,
where patients were then identified by the
presence of at least one PCA administration
during admission. All statistical analyses were
performed using SPSS (IBM Corp. Released
2016. IBM SPSS Statistics for Windows, Version 24.0. Armonk, NY: IBM Corp.).

Results

Study Population

The final sample was comprised of 1,675 adult
individuals during the four calendar years of
data collected. (Table 1) These patients accounted for 2,347 admissions across 23 hospitals in South Carolina, Georgia, and Florida
(site-specific data are shown in Supplemental
Table S1). Patient characteristics likely varied
among the hospitals, but in general, a vast
majority of individuals (n=1,588, 95%) did not
receive a PCA during any encounter. If a patient
received a PCA at any one of their multiple
admissions they were grouped within the PCA
group (n=87, 5%). There were no significant
differences in average age (as determined
at their first admission) between those who
did or did not receive a PCA. Although there
were more females included in the study (58%
females versus 42% males), the PCA utilization
rate overall appeared to be consistent with the
utilization rate within each sex. Demographic
data by similar categories, by each admission

Table 1. Study Population
Characteristics
Total Number of Patients
Age at First Admission (median)

Data
1,675
31.9 years

Male/Female Patients

706/969

Patients with PCA - No. (%)

87 (5.2%)

Patients without PCA – No. (%)
Number of Patients with Multiple Admissions

1,588 (94.8%)
128

Number of Patients with <4 Admissions

1,622

Number of Patients with >4 Admissions

53

Total Number of Admissions
Admissions with PCA – Yes/No

2,347
188/2,159
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Table 2. PCA Impact on LOS in Days
PCA
during
No. Obs
Admission (n=2,347)
Mean

Minimum

Maximum

Median

Std Dev

Variance

No

2,159

5.74

0.09

69.65

4.67

4.64

21.52

Yes

188

4.54

0.28

18.67

3.53

3.34

11.13

instead of individual patients, are presented in
Supplemental Tables S2 and S3.

PCA Utilization and Length of Stay

Of the total 2,347 patient encounters in question, 2,159 (92%) admissions did not show the
presence of at least one PCA, while 188 (8%)
admissions revealed the presence of at least
one PCA. (Table 2) For those admissions with
no presence of PCA usage, the mean LOS was
5.74 days with a median of 4.67 days. For those
admissions with the presence of at least one
PCA, the mean LOS was 4.54 days with a median of 3.53 days (p<0.0001). (Figure 1)
Since our primary research hypothesis was focused on the potential significant relationship
between mean LOS for those admissions that
did and did not receive the administration of at
least one PCA, a Wilcoxon signed-rank test was
computed. A series of normality tests, Kolmogorov-Smirnov and Shapiro-Wilk, were generated to look at the distribution of the PCA
subgroups, no presence and presence, respectively. Since both tests rejected the presence

of normality, a non-parametric approach was
used. A Wilcoxon signed-rank test p-value of
<0.0001 rejected the null hypothesis of no difference between the LOS with/without PCA;
therefore, we could accept that there was a
difference in LOS for those encounters that did
and did not receive at least one PCA.

PCA Use with Frequent Admissions

A secondary analysis was conducted that considered average LOS in frequent admissions by
the same individual. For 1,588 patients who did
not have a documented PCA administration
during any of their encounters, 15 (0.9%) were
admitted four or more times and had a mean
LOS of 7.77 days with a median LOS of 5.59
days, while 1,573 (99%) patients were admitted
fewer than four times and had a mean LOS of
5.89 days and median LOS of 4.75 days. Only
87 out of 1,675 (5%) patients utilized PCA for
pain control. Among these patients, 38 (44%)
were admitted four or more times and had a
mean LOS of 5.29 days with a median LOS of
4.77 days, while 49 (56%) were admitted fewer
than four times and had a mean LOS of 3.82

Figure 1. Non-PCA (Blue) Compared Against PCA (Orange) for Admission LOS - No Outliers
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Table 3. Multiple Admissions and PCA Impact on Mean LOS in Days
PCA
Individual Patient
No. Mean Minimum Maximum
Admissions
Obs
No

Greater than or Equal
(GE) to 4

Std
Dev

Variance

15

7.77

2.63

27.65

5.59

6.18

38.23

1,573

5.89

0.19

69.65

4.75

4.56

20.80

GE to 4

38

5.29

1.39

13.12

4.77

2.98

8.89

Less Than 4

49

3.82

0.31

9.25

3.45

1.93

3.71

Less Than 4
Yes

Median

days with a median LOS of 3.45 days. (Table 3)
When comparing the higher admission frequency groups directly, there appeared to be
greater PCA utilization among those individuals
who were admitted more frequently. Additionally, comparing frequency groups to each other,
PCA use had an approximate 2 day decrease in
average LOS in both frequently and less frequently admitted patients.

Discussion

Overall, our analysis showed that VOCs managed with PCA during a hospital admission for
acute pain resulted in a shorter LOS (mean
4.5+/-3.5; median 3.3 days) versus those not
receiving PCA (mean 5.7 +/-4.6; median 4.6
days). The difference, albeit modest, was
significant (p<0.0001). The LOS is an important hospital metric for reducing cost, reducing
infection risk and expediting the availability
of beds and resources for incoming patients.
Previous research in which PCA was compared
with other methods of pain control in sickle
cell crisis is limited in number and results were
mixed.11-14 LOS for patients in our study was significantly shorter for patients in VOC receiving
PCA (mean 4.5+/-3.5; median 3.3 days) versus
those not receiving PCA (5.7+/-4.6; median 4.6
days). A reviewing of the literature in which our
primary outcome variable, LOS, was previously studied is inconsistent, with some authors
reporting unique ancillary benefits of PCA and
others disputing it. The inconsistent findings
of opioid use with different methods of pain
control in VOC underscores the fact that other
differences between pain control methods
should be considered.12,14
In order to lessen the potential confounding
influence that individual patients with four or
more admissions had in the overall analyses of
the larger group, a secondary analysis to examine LOS among this minority revealed intrigu-

ing results. When comparing 1,622 patients
with three or fewer admissions, the analysis
showed that mean LOS decreased by approximately two days in those who received the PCA
(mean LOS 5.89 days versus 3.82 days), and
median LOS decreased by 1.3 days (median LOS
4.75 days versus 3.45 days). Similarly, among
the 53 patients who had four or more admissions, utilization of PCA decreased their mean
LOS by approximately 2.5 days (mean LOS
7.77 days versus 5.29 days) and median LOS by
approximately 1.2 days (median LOS 5.59 days
versus 4.77). (Table 3) We theorize this result is
because more frequent admissions to the same
hospital could convince the admitting provider
to order PCA rather than scheduling out the
medications. This is likely to be especially true if
the admitting provider could be primed to this
action by viewing electronic medical history
showing that the patient received a PCA prior
during their previous admission.
Another factor that may impact LOS for sickle
cell patients is the time to pain control. Other researchers have found that the ability to
rapidly provide maximum opioid dose reduces
LOS and those with frequent pain were more
likely to benefit.15 Therefore, while LOS is an
important outcome variable, several other factors must be considered when considering pain
management protocols for patients in VOC.
Of the 23 hospital sites included in this study,
only one site (Memorial Health University
Medical Center in Savannah, GA) has a management protocol for treatment of sickle cell
patients with VOC. (Supplemental Figure S2)
This site has the greatest number of patients
included in the analysis, 415 (25%) out of the
1,675 patients; accounting for 814 (34%) out
of 2,347 admissions. Unfortunately, there was
no consistently reliable way to track the time
to PCA within the Meditech electronic health
record at the other sites and therefore a comparison evaluating the protocol’s effectiveness
307
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could not be completed. Additionally, given the
disproportionate number of PCA admissions
coming out of this single site, a comparison
of protocols at other hospitals was not feasible. (Table S1) It is perhaps due to Memorial’s
protocol that PCA utilization rate is greatest
there, but this is unsubstantiated to date.
Furthermore, why this single site accounted
for 34% of all admissions included in the study
is perplexing given that prior incidence studies
within Georgia have not identified Savannah as
an outlier when comparing to other cities and
counties that were also included in the study.16
A thorough review of how Meditech collected
the data at the other sites did not yield any
missing admissions. It has been suggested that
populations such as sickle cell patients tend to
disproportionately present to a single hospital
or practice within their geographic area whose
reputation is known for expertise in sickle cell
care. This could explain why Memorial’s Family
Medicine service, who specializes in VOC care,
had more admissions compared to the other
hospitals surveyed, who had direct competitors
with more renowned sickle cell care clinics.
While our data suggests a benefit to implementing PCA use, some limitations inherent in
a retrospective review are worth noting. This
retrospective study could not account for the
differences in individual provider practice regarding opioid titration and discharge practices, which were not standardized. Secondly, we
could not assess the methods for determining
home opioid and hydroxyurea use, or general
medication adherence, that may impact the
frequent-pain patient admissions and LOS.
Overall there are many other factors independent from pain management that can influence
this metric such as psychosocial issues, opioid
metabolism and tolerance, and differences in
patient reported pain.
Additional prospective research should be conducted in settings of EDs, primary clinics and
inpatient care of this population to better assess pain management protocols and hospital
costs. Ultimately, it is the goal of family physicians to provide appropriate pain management
for patients with SCD experiencing a VOC.
Implementing evidence-based pain management protocols for controlling acute pain crises
of SCD with PCA are necessary for improving
patient-centered care and decreasing LOS.
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Conclusion

Among sickle cell patients who required inpatient hospitalizations, there was a statistically
significant reduction of length of stay for those
who used PCA. These findings support potentially changing hospital protocols to increase
such utilization.
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